{
    "clinical_study": {
        "@rank": "89073", 
        "brief_summary": {
            "textblock": "The primary objective is to compare the phenotype and genotype of the primary tumor with\n      those of its metastases in order to optimize the treatment of metastatic disease, in\n      patients presenting with first metastatic progression of breast cancer."
        }, 
        "brief_title": "Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)", 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        To be eligible to participate in the study, patients must fulfill all of the following\n        criteria:\n\n        Female patients. Age \u2265 18 years. ECOG performance status \u2264 2. Metastatic breast carcinoma,\n        either at diagnosis or at first metastatic relapse.\n\n        Available FFPE +/- frozen primary tumor samples. Evaluable metastatic disease. Metastatic\n        disease outside any previous radiotherapy field (e.g. sub-clavicular or internal mammary\n        lymph nodes).\n\n        Metastatic disease accessible to either percutaneous or surgical sampling. Signed written\n        informed consent (approved by an Independent Ethics Committee and obtained prior to any\n        study-specific screening procedure).\n\n        Social and psychological welfare in concordance with compliance to the study.\n\n        Exclusion Criteria:\n\n        To be eligible to participate in the study, patients must fulfill none of the following\n        criteria:\n\n        Bilateral or multifocal breast cancer. Isolated local or contralateral relapse.\n\n        Solitary bone and/or brain metastatic disease unless :\n\n        Metastatic sites eligible for a therapeutic surgery. Metastatic sites sampled for\n        diagnosis purpose. Past or current history of malignant neoplasms, except for curatively\n        treated basal and squamous cell carcinoma of the skin. Carcinoma in situ of the cervix.\n        Any coagulopathy contraindicating tumor biopsy. Presence of a contraindication to general\n        anesthesia, if required."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956552", 
            "org_study_id": "IC 2009-05"
        }, 
        "intervention": {
            "intervention_name": "biopsy or cytopuncture", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic breast cancer", 
            "Tumor biopsy", 
            "Phenotype and genotype characterization"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Centre Oscar Lambret"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes Saint Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "INSTITUT DE CANCEROLOGIE DE L'OUEST Ren\u00e9 Gauducheau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75004"
                    }, 
                    "name": "Hopital Saint Louis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75005"
                    }, 
                    "name": "Institut Curie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-cloud", 
                        "country": "France", 
                        "zip": "92210"
                    }, 
                    "name": "Institut Curie HOPITAL RENE HUGUENIN"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94800"
                    }, 
                    "name": "Institut Gustave Roussy"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "official_title": "Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting", 
        "overall_official": {
            "affiliation": "Institut Curie", 
            "last_name": "SIGAL BRIGITTE, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess the phenotype ant genotype discrepancies regarding hormonal receptor, FISH status and proliferation between the primary tumor and the first metastatic progression.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Institut Curie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Curie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Intervention Model: Single Group Assignment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}